phone

Erectile Dysfunction - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 112
  • Category: Pharmaceuticals
  • Country: Global
Erectile Dysfunction - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2017, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 4, 5, 3, 2, 13, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 7
Global Markets Direct Report Coverage 7
Erectile Dysfunction - Overview 8
Erectile Dysfunction - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Erectile Dysfunction - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Erectile Dysfunction - Companies Involved in Therapeutics Development 25
Apricus Biosciences Inc 25
Astellas Pharma Inc 25
Biolab Farmaceutica Ltda 26
Biopharm GmbH 26
Can-Fite BioPharma Ltd 27
Fabre-Kramer Pharmaceuticals Inc 27
Futura Medical Plc 28
Hanmi Pharmaceuticals Co Ltd 28
Humanetics Corp 29
IntelGenx Corp 29
Ion Channel Innovations LLC 30
iX Biopharma Ltd 30
Mezzion Pharma Co Ltd 31
Mitsubishi Tanabe Pharma Corp 31
Monosol Rx LLC 32
N4 Pharma Plc 32
NAL Pharmaceuticals Ltd 33
Nanoform Cardiovascular Therapeutics Ltd 33
Palatin Technologies Inc 34
Pharmicell Co Ltd 34
SK Chemicals Co Ltd 35
Suda Ltd 35
XuanZhu Pharma Co Ltd 36
Yangtze River Pharmaceutical Group 36
Yungjin Pharm Co Ltd 37
Erectile Dysfunction - Drug Profiles 38
alprostadil - Drug Profile 38
AP-185 - Drug Profile 45
avanafil - Drug Profile 46
BIO-300 - Drug Profile 48
BL-214 - Drug Profile 51
Cellgram-ED - Drug Profile 52
CF-602 - Drug Profile 53
fadanafil - Drug Profile 55
FKK-01PD - Drug Profile 56
HCP-1302 - Drug Profile 57
IPED-2015 - Drug Profile 58
MED-2002 - Drug Profile 59
MED-2005 - Drug Profile 62
mirabegron ER - Drug Profile 63
moxisylyte - Drug Profile 67
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile 68
pVAX-hSlo - Drug Profile 70
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinsons Disease - Drug Profile 72
sildenafil - Drug Profile 74
sildenafil citrate - Drug Profile 75
sildenafil citrate - Drug Profile 76
sildenafil citrate - Drug Profile 77
sildenafil citrate - Drug Profile 78
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile 79
SUD-003 - Drug Profile 80
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 82
T-6932 - Drug Profile 83
tadalafil - Drug Profile 84
tadalafil - Drug Profile 86
tadalafil - Drug Profile 87
tadalafil - Drug Profile 88
tadalafil - Drug Profile 89
TF-0092 - Drug Profile 90
TPN-729 - Drug Profile 91
TR-399 - Drug Profile 92
udenafil - Drug Profile 93
YBH-1603 - Drug Profile 97
Yonkenafil - Drug Profile 98
Erectile Dysfunction - Dormant Projects 99
Erectile Dysfunction - Discontinued Products 101
Erectile Dysfunction - Product Development Milestones 102
Featured News & Press Releases 102
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110

List Of Tables


Number of Products under Development for Erectile Dysfunction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2017
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2017
Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H2 2017
Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2017
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017
Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2017
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2017
Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2017
Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H2 2017
Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H2 2017
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2017
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Erectile Dysfunction - Pipeline by Monosol Rx LLC, H2 2017
Erectile Dysfunction - Pipeline by N4 Pharma Plc, H2 2017
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
Erectile Dysfunction - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017
Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2017
Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2017
Erectile Dysfunction - Pipeline by Suda Ltd, H2 2017
Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2017
Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H2 2017
Erectile Dysfunction - Dormant Projects, H2 2017
Erectile Dysfunction - Dormant Projects, H2 2017 (Contd..1), H2 2017
Erectile Dysfunction - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Erectile Dysfunction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Erectile Dysfunction - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2017, provides an overview of the Erectile Dysfunction

View Report

Erectile Dysfunction -Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Erectile Dysfunction. The key objective of the report is to establish the understanding for all

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports